{"id":481243,"title":"Notice: Prescription Drug List (PDL): Casirivimab and Imdevimab (COVID-19) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-06","captureTimestamp":"2026-01-06T16:13:14.177000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/amendment-casirivimab-imdevimab-covid19.html?wbdisable=true","snippet":"Notice: Prescription Drug List (PDL): Casirivimab and Imdevimab (COVID-19) Date: June 17, 2021 Our file number: 21-111549-461 The purpose of this Notice of Amendment is to notify about the addition of casirivimab and imdevimab to the Prescription Drug List (PDL) for human and…","rawSnapshotUrl":"/api/snapshots/raw/481243","browseUrl":"https://replay.healtharchive.ca/job-6/20260106161314/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/amendment-casirivimab-imdevimab-covid19.html?wbdisable=true#ha_snapshot=481243","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}